Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

3 approaches for AI adoption in life sciences and biopharma

Go deeper to find solutions.

[Photo: Getty Images]

Profile photo of Rajat Mishra

Founder & CEO · Prezent

AI is everywhere in 2026, with the data suggesting adoption rates are surging. According to McKinsey, 65% of professionals now report that their organizations regularly use GenAI, representing a 33% increase in just over a year. However, adoption rates are far from consistent across the board.

GenAI can be applied to certain tasks and functions, such as repetitive processes that rely on text and data and don’t require extensive, expensive digital transformation. The first wave of AI adoption concentrated on low-hanging fruit, allowing companies to reap immediate efficiency gains from the technology.

So while particular companies—such as agile startups and disruptive tech companies—have higher adoption rates, leaping headfirst into AI won’t work in highly regulated industries such as life sciences and biopharmaceuticals due to stricter compliance, privacy, and accountability requirements.

However, the impact potential in these massive markets makes the case for finding an approach that works. Valued at $666.41 billion in 2025, the global biopharmaceuticals market is projected to exceed $1.4 trillion by 2034. Meanwhile, the global life sciences market grew to $98.63 billion in 2025 and is projected to reach around $269.56 billion by 2034.

For the U.S. specifically, these industries are critical. Roughly two-thirds of new drugs entering the global market in the last decade originated in the U.S., highlighting the nation’s important role in drug discovery and pharmaceutical innovation.

In 2026, AI will gain traction in life sciences and biopharmaceuticals, but the key to success is AI that goes deep into the vertical, which means building AI tools that are specifically trained on, and designed for, the workflows, terminology, regulations, and data of biopharma and life sciences.

3 approaches for AI adoption in biopharma and life sciences

Here are three things to keep in mind.

1. AI bolt-ons don’t work

AI’s benefits to drug discovery and the research and development (R&D) lifecycle are still emerging, but large biopharma isn’t taking a wait-and-see approach. AI adoption among large biopharma is nearly three times that of smaller companies, according to Benchling.

However, pharma leaders believe successful AI deployment in their industry requires going deep into the vertical. A well-integrated stack enables AI for things like drug discovery and also determines how well these tools can scale to move beyond pilots and operational silos.

In addition, behavior change is just as important as the tech stack being implemented. You can have the most advanced platform in the world, but if your team doesn’t trust it or know how to integrate it into their workflow, the return on investment is zero. Onboarding, training, peer sharing, and role modeling boost success.

2. Contextual AI is mission-critical

Beyond drug discovery and R&D, AI can also support other areas of operation.

Administrative work automation is one obvious example, but the technology also supports much more complex and strategic outputs. An AI-first approach can supercharge company culture and free senior leaders to focus on higher-order decisions.

For example, the R&D process is complex, and the success of research and trials also depends on a variety of other factors, such as how well companies can recruit top scientists, secure backing from major funders, or deliver proposals to government stakeholders.

Here, AI can support the industry across a range of administrative tasks, such as crafting presentations, writing reports, and managing internal communications.

Although current GenAI models are impressive, it’s important to remember that the stakes in life sciences and biopharma are unique. To truly impact drug development, clinical trials, and medical affairs, companies need AI with contextual intelligence that understands industry nuances.

3. Reinvention and innovation are competitive advantages

Although both the life sciences and biopharma markets are projected to grow substantially in the years ahead, they’re also facing tough odds. Despite an impressive wave of new drug approvals over the past five years, PwC notes that the pharma industry underperformed in the capital markets over that same period.

Companies pursuing similar therapeutic areas fuel intense head-to-head competition and compress returns. Companies will seek a competitive advantage on other fronts amid this fierce competition.

The industries’ highly regulated nature means that a risk-averse approach to innovation is the standard. However, the future belongs to those who have the courage to tinker with new tools in a regulated environment to find the breakthroughs.

Pharma industry-supporting agencies must offer an equally competitive stance, providing high-quality deliverables with fast turnaround times at competitive price points. This will be achieved by heavily integrating AI into their service offerings.

AI’s next adoption wave will be fueled by leaders who recognize that life science and biopharma companies must move beyond general-purpose tools by going deep into their verticals.

Rajat Mishra is the CEO of Prezent.